Roche Secures CE Mark for Innovative Multiple Sclerosis Blood Test

Roche has announced receiving the CE mark for its Elecsys NfL test, a diagnostic tool designed to detect neuroinflammation and nerve cell damage in patients with multiple sclerosis (MS). This regulatory approval allows the test to be utilized across European markets, specifically targeting those diagnosed with relapsing-remitting multiple sclerosis (RRMS). The test offers a minimally invasive alternative to traditional monitoring methods by measuring the NfL protein directly from a simple blood sample. By providing clinicians with a reliable way to monitor biological damage, Roche aims to significantly improve the long-term management of the disease. This development strengthens Roche's competitive position within the global diagnostics and neurology sectors. Market analysts view this expansion of the diagnostic portfolio as a positive step that supports the company's long-term revenue growth potential.